questionText: To ask the Secretary of State for Health and Social Care, if he will publish the cost-benefit modelling for the prescription of (a) donanemab and (b) lecanemab for patients with early-stage Alzheimer’s disease.
answerText: The National Institute for Health and Care Excellence has published the company’s evidence submission, which includes the company’s evidence on costs and benefits, and the external assessment group report, which assesses the company’s evidence submission ...
heading: Alzheimer's Disease: Drugs